treatment. GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge also significantly decreased eosinophilia and type 2 cytokine and chemokine expression in the airway after 4 days of Alternaria extract challenge. Conclusion: These results reveal that GLP-1R signaling might be a therapy to reduce IL-33 release and inhibit the ILC2 response to protease-containing aeroallergens, such as Alternaria. (J Allergy Clin Immunol 2018;142:1515-28.)
Key words: Glucagon-like peptide 1 receptor, liraglutide, group 2 innate lymphoid cells, IL-33, Alternaria IL-33 is one of the most consistently associated gene candidates for asthma identified by using genome-wide association studies in diverse ethnic groups.
1-4 IL-33 is predominantly produced by epithelial cells in response to protease-containing aeroallergens, and its release is mediated by dual oxidase 1 (DUOX1). 5 IL-33 activates group 2 innate lymphoid cells (ILC2s) to produce the type 2 cytokines IL-5 and IL-13, which initiate innate immunity-driven allergic responses. 6, 7 In addition, IL-33 polarizes naive CD4 T cells to differentiate into effector T H 2 cells, which produce IL-4, IL-5, and IL-13 and are responsible for adaptive immunity-mediated allergeninduced responses. 8 Therefore IL-33 is a central mediator of both innate and adaptive immunity-regulated allergic inflammation in the lung and has a role in the pathogenesis of conditions, such as asthma. Also, IL-33 has been deemed to be an important therapeutic target in inhibiting allergic diseases. 9 However, to our knowledge, there have been no reports identifying pharmacologic agents that inhibit lung IL-33 protein release or expression.
Glucagon-like peptide 1 (GLP-1) is a peptide hormone synthesized and released by enteroendocrine L-cells in the ileum and large intestine after oral food intake. 10 GLP-1 has a role in glycemic control by inducing glucose-dependent insulin secretion from b cells and inhibiting glucagon release from a cells in the pancreas. 11, 12 GLP-1 also induces weight loss by promoting satiety. 13 Glucagon-like peptide 1 receptor (GLP-1R) agonists, such as liraglutide and exenatide, are approved by the US Food and Drug Administration (FDA) for treatment of type 2 diabetes (T2D). 14, 15 Several studies report that GLP-1R agonists had anti-inflammatory effects in patients with multiple disorders, including T2D. For instance, GLP-1R agonist administration decreased TNF-a and IL-6 production by PBMCs of obese patients with T2D 16 and diabetic mouse adipose tissue. 17 In addition, the GLP-1R agonist exendin 4 reduced serum inflammatory cytokines during LPS-induced endotoxemia, 18 liver inflammation, and aortic atherosclerosis in a rodent model. 19 These data indicate that GLP-1R agonists downregulate innate inflammatory responses to endotoxins or endogenous inflammatory mediators. Furthermore, it has been reported that liraglutide attenuated bleomycin-induced pulmonary fibrosis 20 and OVAinduced chronic airway inflammation. 21 These results suggest the possibility of novel therapeutic strategies for chronic lung diseases using GLP-1R agonists. However, no studies have reported the effect of GLP-1R agonists on lung IL-33 expression or release or the effect of GLP-1R agonists on the innate allergic inflammatory response mediated by ILC2s.
In this study we performed airway challenge in mice with an extract of Alternaria alternata, an aeroallergen with protease activity that is associated with severe asthma exacerbations. 22, 23 GLP-1R agonist or vehicle treatment was started either 2 days before the first Alternaria extract challenge or 1 day after the first Alternaria extract challenge. We found that treatment with the GLP-1R agonist liraglutide starting 2 days before the first Alternaria extract challenge inhibited IL-33 expression and release in the lung or into the bronchoalveolar lavage (BAL) fluid. Furthermore, GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge inhibited lung Duox1 expression, providing a potential mechanism by which GLP-1R signaling inhibits lung IL-33 release in response to aeroallergen challenge. In addition, we found that GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge inhibited IL-5 and IL-13 production from lung ILC2s, blunted airway mucus and responsiveness, and reduced lung eosinophilia. GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge also reduced the eosinophilia and type 2 cytokines and chemokines in the airways. This report is the first to identify an FDA-approved pharmacologic agent that inhibits lung IL-33 release, providing an alternative to biologic therapies that target IL-33-mediated diseases.
METHODS Mice
Nine-to 12-week-old female wild-type (WT) BALB/c mice were obtained from Jackson Laboratories (Bar Harbor, Me). IL-33
Citrine/1 reporter mice were generated by crossbreeding WT BALB/c and IL-33
Citrine/Citrine (IL-33 knockout) mice, which are the kind gift of Dr Andrew N. J. McKenzie. 24 Transgenic mice expressing mApple protein under the control of the GLP-1R promoter were generated, as previously described. 25 Animal experiments were approved by the Institutional Animal Care and Use Committee at Vanderbilt University and were conducted according to the ''Guidelines for the care and use of laboratory animals'' prepared by the Institute of Laboratory Animal Resources, National Research Council.
GLP-1R agonist treatment and Alternaria or house dust mite extract challenge in a mouse model of allergic inflammation
In the protocol in which GLP-1R agonist treatment was started 2 days before the first Alternaria extract challenge, the GLP-1R agonist liraglutide In the protocol in which GLP-1R agonist was started 1 day after the first Alternaria extract challenge, vehicle was administered from day 22 to day 0, and then either GLP-1R agonist or vehicle was administered from day 1 to day 3. From day 0 to day 3, either 5 mg (protein amount) of Alternaria extract in 100 mL of PBS, 25 mg (protein amount) of HDM extract in 100 mL of PBS, or 100 mL of PBS as vehicle was used as an intranasal challenge to mice anesthetized with ketamine/xylazine. Mice were killed, and BAL fluid and whole lungs were harvested 1 hour after the first challenge of Alternaria extract or vehicle (for IL-33 release) or 24 (for cytokine measurement) or 48 (for histopathology and airways responsiveness measurement) hours after the last challenge of Alternaria extract, HDM extract, or PBS.
Flow cytometry
Harvested lungs were minced and digested with collagenase IV (1 mg/mL; Sigma-Aldrich, St Louis, Mo) and DNase I (50 IU/mL; Sigma-Aldrich) in 
Statistical analysis
All data were analyzed with GraphPad Prism 5 software (GraphPad Software, La Jolla, Calif). P values were calculated by means of 1-way ANOVA with the Bonferroni multiple-pairs comparisons test. P values of less than .05 were considered significant between 2 groups.
Additional details on the methods used in this study are available in the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS

GLP-1R expression on lung epithelial cells
We sought to examine whether GLP-1R expression was present on lung epithelial cells to determine whether GLP-1 could directly modulate epithelial cell function. GLP1R mRNA expression was detected in normal human lung tissue and mouse lung tissue (Fig 1, A and B) . Furthermore, GLP-1R protein expression was also detected on mouse lung epithelial cells and endothelial cells (Fig 1, C and D) using GLP-1R/mApple reporter mice. These results provide a rationale for investigating the effect of GLP-1R signaling in response to airway Alternaria extract challenge.
GLP-1R agonist treatment suppresses Alternaria extract-induced IL-33 expression in lung epithelial cells IL-33 is a key activator of the innate allergic airway response, and in particular, IL-33 stimulates ILC2s. 6 Therefore we tested whether GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge decreases IL-33 protein expression after airway Alternaria extract challenge for 4 consecutive days (Fig 2, A) . To confirm the localization of IL-33 expression and the effect of GLP-1R agonist on a per-cell IL-33 expression level, we used IL-33
Citrine/1 reporter mice. We found that Alternaria extract challenge significantly increased mean fluorescence intensity of citrine fluorescence 
GLP-1R agonist treatment suppresses Alternaria extract-induced IL-33 release but not lactate dehydrogenase activity in BAL fluid
Airborne allergens, such as Alternaria, have proteolytic activity, which induces IL-33 release in BAL fluid 1 hour after airway administration through protease-activated receptor 2 signaling. 26 Therefore we measured IL-33 protein levels in BAL fluid 1 hour after the first Alternaria extract challenge after GLP-1R agonist treatment or vehicle treatment starting 2 days before the first Alternaria extract challenge (Fig 3, A) . Alternaria extract challenge significantly increased protein levels of IL-33 in BAL fluid compared with those in PBS-challenged groups. The Alternaria extract-induced IL-33 level in BAL fluid was significantly decreased by GLP-1R agonist treatment compared with the vehicle treatment (Fig 3, B) .
Next, we measured lactate dehydrogenase (LDH) activity in BAL fluid to assess the effect of GLP-1R agonist treatment for lung cell damage during IL-33 release. Alternaria extract challenge significantly increased LDH activity in BAL fluid compared with that in PBS-challenged groups (see Fig E1, B, in this article's Online Repository at www.jacionline.org). Although the Alternaria extract-induced LDH activity was not decreased in the GLP-1R agonist treatment group compared with the vehicle treatment group (see Fig E1, B) , Alternaria extract-induced IL-33 protein levels were significantly decreased in BAL fluid from the GLP-1R agonist treatment group compared with the vehicle treatment group (see Fig E1, A). These results indicate that the effect of GLP-1R signaling on the IL-33 release pathway is independent of Alternaria extract-induced lung cell damage.
A previous study reported that Alternaria extract directly and quickly induced mast cell degradation and activation producing CysLTs and PGD 2 .
27 Therefore we measured CysLT and PGD 2 levels in BAL fluid to assess an effect of GLP-1R agonist In addition, we measured GLP-1R protein expression on bone marrow-derived cultured mast cells (BMCMCs) using GLP-1R/mApple reporter mice. The BMCMC gating strategy was shown in Fig E1, E. GLP-1R/mApple expression was not detected on the BMCMCs (Fig E1, F) , supporting the idea that the GLP-1R agonist does not have a direct effect on mast cell biology.
Furthermore, induction of LDH activity and CysLT and PGD 2 levels by Alternaria extract challenge was observed in both IL-33 knockout and WT mice (see Fig E1, B-D) . Therefore the Alternaria extract-induced cell damage and production of lipid mediators are independent of biological effects of endogenous IL-33. Taken together, these results reveal that GLP-1R agonist treatment suppresses acute IL-33 release after Alternaria extract challenge but does not suppress lung cell damage and production of CysLTs and PGD 2 from lung-resident cells, such as mast cells.
GLP-1R agonist treatment suppresses Duox1 mRNA expression in the Alternaria extract-challenged lung DUOX1 is a critical mediator of IL-33 release from lung epithelial cells after aeroallergen challenge. 5 Therefore we measured mRNA expression of Duox1 in the lung 1 hour after Alternaria extract challenge, the time of peak IL-33 release, and after GLP-1R agonist or vehicle treatment. Lung Duox1 mRNA expression was significantly decreased by GLP-1R agonist treatment compared with vehicle treatment (Fig 3, C) . This result suggests a possible mechanism by which GLP-1R agonist suppressed IL-33 release.
GLP-1R agonist treatment suppresses the number of mouse lung ILC2s expressing IL-5 and IL-13 in response to airway Alternaria extract challenge Because IL-33 is an important stimulus for the innate allergic immune response, we sought to determine whether GLP-1R signaling inhibited ILC2 function. First, we measured GLP-1R expression on lung ILC2s using GLP-1R/mApple reporter mice to reveal whether the GLP-1R agonist directly regulates ILC2s. The gating strategy for ILC2s is shown in Fig E2. ILC2s A, Cell differentials in BAL fluid harvested 24 hours after the last Alternaria extract challenge (n 5 6 for PBS-challenged groups and n 5 11 for Alternaria extract-challenged groups). Eos, Eosinophils; Lymph, lymphocytes; Mac, macrophages; Neu, neutrophils. B and C, Representative sections (Fig 6, B) and eosinophil scores (Fig 6, C) , as determined by using anti-major basic protein antibody staining (n 5 5 for each group). D and E, Representative sections (Fig 6, D) and mucus scores (Fig 6, E) , as determined by using PAS staining (n 5 4 for PBS-challenged groups and n 5 10 for Alternaria extract-challenged groups). Lungs for histologic analysis were harvested 48 hours after the last Alternaria extract challenge. F, Airway resistance to challenge with increasing doses of methacholine (n 5 7 for PBS-challenged groups and n 5 16 for Alternaria extract-challenged groups). *P < .05 compared with vehicle-PBS and **P < .05 compared with vehicleAlternaria. All results are combined with 2 independent experiments and shown as means 6 SEMs. MCh, Methacholine; Veh, vehicle. *P < .05. 
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, and IL-13 1 lung ILC2s (Fig 4,  B-D A, Mice were challenged with Alternaria extract intranasally for 4 consecutive days (from day 0 to day 3). Mice of the vehicle treatment group and the group with GLP-1R agonist treatment starting 2 days before the first Alternaria challenge were treated with vehicle or GLP-1R agonist, respectively, from day 22 to day 3. Mice undergoing GLP-1R agonist treatment starting 1 day after the first Alternaria challenge were treated with vehicle from day 22 to day 0 and then treated with GLP-1R agonist from day 1 to day 3. B, Cell differentials in BAL fluid harvested 24 hours after the last Alternaria extract challenge. C and D, BAL fluid (Fig 7, C) and lungs (Fig 7, D) were harvested 24 hours after the last Alternaria extract challenge to measure the protein expression of IL-4, IL-5, IL-9, IL-13, CCL11, CCL17, CCL22, and CCL24 by using ELISA. Results are combined with 2 independent experiments and shown as means 6 SEMs of 10 mice in each group. *P < .05.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 5 extract-induced CD4 T cells expressing IL-13 but not IL-5. In the Alternaria extract-challenged groups there was a statistically significant 10-fold increase in the number of IL-5 1 ILC2s (Fig 4, C) compared with IL-5 1 CD4 T cells (see Fig  E4, C) and a 2.4-fold increase in the number of IL-13 1 ILC2s (Fig 4, D) compared with IL-13 1 CD4 T cells (see Fig E4, D) . The fold change between numbers of ILC2s and CD4 T cells expressing IL-5 and IL-13 are similar to our previous report. 28 Therefore these results indicate that ILC2s, but not CD4 T cells, are the major source of IL-5 and IL-13 in response to this 4 consecutive day airway Alternaria extract challenge protocol and that GLP-1R signaling likely inhibits this early innate allergic immune response through reduction of IL-33 release in the lung.
GLP-1R agonist treatment suppresses Alternaria extract-induced cytokine and chemokine expression in the lung and airway
Next, we measured protein levels of type 2 cytokines and chemokines in BAL fluid and lung homogenates. Alternaria extract challenge increased significantly the protein expression of IL-4, IL-5, IL-13, CCL11 (eotaxin), CCL17 (thymus and activation-regulated chemokine [TARC]), CCL22 (macrophage-derived chemokine), and CCL24 (eotaxin 2) in both BAL fluid and lung homogenates compared with that seen in PBS-challenged groups. IL-9 levels were significantly increased in the lung homogenate, but not BAL fluid, after Alternaria extract challenge. We found a statistically significant decrease in Alternaria extract-induced protein expression of IL-5, IL-13, CCL17, CCL22, and CCL24 in both BAL fluid and lung homogenates from GLP-1R agonist-treated mice compared with vehicle-treated mice (Fig 5) . In addition, Alternaria extractinduced IL-4, IL-9, and CCL11 protein expression was also decreased in lung homogenates from GLP-1R agonist-treated mice compared with vehicle-treated mice.
GLP-1R agonist treatment suppresses eosinophilia, mucus production, and airway responsiveness in response to airway Alternaria extract challenge Based on our finding that GLP-1R agonist treatment significantly decreased protein expression of Alternaria extractinduced IL-5, CCL11, and CCL24, which are associated with eosinophil recruitment, we hypothesized that GLP-1R agonist treatment decreases eosinophil accumulation in the lung after Alternaria extract challenge. To test this hypothesis, we measured BAL fluid cell counts and differentials and assessed perivascular eosinophils using immunohistopathology. Alternaria extract challenge significantly increased total BAL fluid cell, macrophage, eosinophil, lymphocyte, and neutrophil numbers compared with those in the PBS-challenged groups. GLP-1R agonist treatment significantly decreased Alternaria extractinduced total BAL fluid cell, macrophage, eosinophil, and lymphocyte numbers compared with those seen after vehicle treatment (Fig 6, A) . Furthermore, we found that GLP-1R agonist treatment resulted in a significant decrease in Alternaria extractinduced perivascular eosinophil numbers in the lung compared with those after vehicle treatment using immunohistopathology (Fig 6, B and C) . IL-13 is a critical inducer of airway mucus production. 29 We found that GLP-1R agonist treatment decreased protein levels of IL-13 in the lung. Therefore we tested the hypothesis that GLP-1R agonist treatment suppresses mucus production in the airway after Alternaria extract challenge. There was no mucus and there were no mucus-producing cells in the lungs of mice challenged with PBS. Alternaria extract challenge significantly increased mucus production on large airway epithelial cells. GLP-1R agonist treatment significantly decreased Alternaria extract-induced mucus production compared with vehicle treatment (Fig 6, D and E) . These results indicate that GLP-1R agonist treatment suppresses acute eosinophilic lung inflammation and airway mucus production in innate allergic immune responses to Alternaria extract challenge.
We found that GLP-1R agonist treatment significantly decreased asthma-like airway inflammation after Alternaria extract challenge for 4 consecutive days compared with vehicle treatment. We next tested the hypothesis that GLP-1R agonist treatment decreases AR in Alternaria extract-challenged mice. Alternaria extract challenge significantly increased airway responsiveness (AR) compared with PBS challenge. GLP-1R agonist treatment significantly decreased Alternaria extractinduced AR compared with that seen after vehicle treatment (Fig 6, F) .
GLP-1R agonist treatment suppresses HDM extract-induced IL-5, IL-13, and IL-33 in the lung
To assess the effects of GLP-1R agonist treatment in a different antigen-induced innate allergic inflammation model, we used HDM extract because HDM is one of the common antigens associated with allergic asthma and atopic dermatitis. 30 First, we measured IL-33 protein levels and LDH activity in BAL fluid 1 hour after the first HDM extract challenge after GLP-1R agonist or vehicle treatment (see Fig E5, A, in this article's Online Repository at www.jacionline.org). However, IL-33 protein was not detected in either the BAL fluid from the HDM extract-challenged or PBS-challenged groups (see Fig E5, B) , and there was no difference in BAL fluid LDH activity between the HDM extract-and PBS-challenged groups (see Fig E5, B) . These results indicate that HDM extract has no cytolytic activity to induce IL-33 release. Meanwhile, 4 consecutive days of HDM extract challenge increased protein levels of IL-5, IL-13, and IL-33 in lung homogenates 24 hours after the last HDM extract challenge compared with those after PBS challenge (see Fig E5, D) . HDM extractinduced IL-5, IL-13, and IL-33 levels were significantly decreased in the GLP-1R agonist treatment group compared with those in the vehicle treatment group (see Fig E5, D) . This result revealed that GLP-1R agonist treatment decreased type 2 cytokine and IL-33 expression caused by HDM extract-induced innate inflammation.
GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge, as well as treatment starting 2 days before the first Alternaria extract challenge, suppresses Alternaria extractinduced eosinophilia and type 2 cytokine and chemokine expression in the airway
To determine the effect of GLP-1R agonist treatment as a potential therapeutic use, we compared the effect of GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge against treatment starting 2 days before the first Alternaria extract challenge in the setting of Alternaria extractinduced innate allergic inflammation (Fig 7, A) . GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge significantly decreased the number of Alternaria extract-induced total BAL fluid cells, eosinophils, and lymphocytes compared with vehicle treatment similar to the effect of GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge (Fig 7, B) . Alternaria extract-induced IL-5, CCL11, CCL17, CCL22, and CCL24 levels in both BAL fluid and lung homogenates were significantly decreased by GLP-1R agonist treatment in both protocols compared with vehicle treatment (Fig 7, C and D) . Alternaria extract-induced IL-13 levels in BAL fluid and IL-9 levels in lung homogenates were also significantly decreased in the GLP-1R agonist treatment group starting 1 day after the first Alternaria extract challenge compared with vehicle treatment (Fig 7, C and D) . These results suggest that GLP-1R agonist treatment after initial antigen challenge also suppresses Alternaria extract-induced airway eosinophilia and type 2 cytokine and chemokine expression in the airway and lung.
DISCUSSION
Our results show that a GLP-1R agonist inhibited lung epithelial expression and airway release of IL-33 in response to the clinically relevant, protease-containing ubiquitous aeroallergen Alternaria alternata. This is the first report of an FDAapproved pharmacologic agent inhibiting allergen-induced lung IL-33 expression and release, and this finding has significant implications because it might provide an alternative to biologic therapies, such as mAbs or receptor antagonists, that target IL-33-mediated diseases. In addition, Duox1 mRNA expression was also decreased by GLP-1R agonist treatment during IL-33 release after Alternaria extract challenge. Furthermore, we found that GLP-1R agonist treatment 2 days before the first Alternaria extract challenge significantly decreased the number of lung ILC2s expressing IL-5 and IL-13 after 4 consecutive days of Alternaria extract challenge. GLP-1R agonist treatment 2 days before the first Alternaria extract challenge significantly decreased IL-4, IL-5, IL-9, IL-13, CCL11, CCL17, CCL22, and CCL24 protein expression in the lung homogenates, the number of eosinophils in BAL fluid and perivascular eosinophil accumulation, mucus production, and AR induced by the Alternaria extract challenge. Likewise, GLP-1R agonist starting 1 day after the first Alternaria extract challenge significantly decreased eosinophilia and IL-5, IL-13, CCL11, CCL17, CCL22, and CCL24 levels in the airway. These results suggest that GLP-1R signaling not only has an effect on the initial allergen-induced IL-33 release in the airway but also inhibits established airway inflammation.
GLP-1R is abundantly expressed in human and mouse lung, heart, brain, and kidney, as well as pancreas, 31, 32 tissue, and many studies indicate the therapeutic effect of GLP-1R signaling for diseases in multiple tissues. For instance, the GLP-1R agonist exendin-4 improved atherosclerosis by reducing macrophage adhesion to endothelial cells, as well as by reducing serum glucose levels. 32 GLP-1 peptide treatment decreased irradiationor LPS-induced proinflammatory cytokine expression in the brain and astrocytes in a mouse model. 33, 34 In addition, GLP-1R agonist decreased chronic lung inflammation in a mouse model of OVA sensitization combined with 66 days of OVA challenge 21 and reduced mortality and airway resistance in a mouse model of obstructive lung disease induced by OVA and LPS challenge. 35 Binding of GLP-1 to its G protein-coupled receptor causes adenylate cyclase activation, resulting in formation of cyclic AMP (cAMP). Subsequent activation of protein kinase A and the cAMP-regulated guanine nucleotide exchange factor II leads to an increase in intracellular calcium concentrations and enhanced exocytosis of insulin-containing granules in pancreatic b cells. 36 Furthermore, b 2 -adrenergic receptor signaling also activates the cAMP/protein kinase A signaling pathway, which then relaxed airway smooth muscle and reduced airway mucus secretion. 37 Our group reported that PGI 2 receptor signaling downregulated dendritic cell (DC), T-cell, and ILC2 activation mediated by cAMP induction. [38] [39] [40] In addition, GLP-1R agonist reduced inflammatory responses in mouse peritoneal macrophages stimulated with LPS through the cAMP signaling pathway. 32 These results suggest that cAMP induction by GLP-1R agonist, as well as b 2 -adrenergic agonist or PGI 2 , might have suppressive effects on activation of immune cells that express GLP-1R.
In this study we found that GLP-1R agonist treatment downregulated Alternaria extract-induced IL-33 release and expression. IL-33 plays important roles in type 2 innate immunity after helminth infection or after exposure to protease-containing aeroallergens. 26, 41 Biologically active full-length IL-33 is released into the extracellular space after cell damage, such as necrosis, and then IL-33 activates many types of immune cells, including CD4 T cells, mast cells, basophils, macrophages, DCs, and epithelial cells, as well as ILC2s. 42, 43 IL-33 is likely to be a first alarm signal because of its constitutive expression in normal epithelial and endothelial cells 43 and is ready to be released after infection or mechanical cell damage. We found that GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge reduced IL-33 release and Duox1 mRNA expression, but not LDH activity, after the first Alternaria extract challenge. These results suggest that GLP-1R signaling downregulates the IL-33 release pathway in lung epithelial cells expressing IL-33 without suppression of the cell damage. Hristova et al 5 reported that Alternaria induced IL-33 release in cultured primary human bronchial epithelial cells depended critically on DUOX1-mediated activation. Shiraki et al 44 reported that GLP-1R signaling inhibited NADPH oxidase activation in primary human endothelial cells. Taken together, our findings suggest that GLP-1R signaling decreases Duox1 expression in lung epithelial cells, thus inhibiting Alternaria extract-induced IL-33 secretion.
The reduction in IL-33 protein levels to airway Alternaria extract challenge mediated by the GLP-1R agonist is one possible mechanism by which GLP-1R signaling reduced IL-5-and IL-13-expressing ILC2 numbers and protein levels of CCL11, CCL24, TARC, and macrophage-derived chemokine in the airway and lung after 4 consecutive days of Alternaria extract challenge. These findings are consistent with previous reports that IL-33 induced IL-5 and IL-13 expression by ILC2s in a dose-dependent fashion, 45 CCL11 expression by fibroblasts, 46 and TARC expression by DCs. 47 Although GLP-1R signaling reduced the number of IL-5-and IL-13-expressing ILC2s after 4 consecutive days of Alternaria extract challenge, the percentage of IL-5-and IL-13-expressing ILC2s was not decreased. Intracellular cytokine staining is appropriate to determine the cells that have the ability to express IL-5 and IL-13; however, cell activation by such a strong stimulus as phorbol 12-myristate 13-acetate and ionomycin might prevent the evaluation of the precise quantitative cytokine expression level in individual cells.
Meanwhile, we found that GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge significantly decreased IL-5, IL-13, and IL-33 expression in the lung after 4 consecutive days of HDM extract challenge. This HDM extract-induced innate inflammation was induced without IL-33 release. Furthermore, GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge also significantly decreased eosinophilia and type 2 cytokine and chemokine expression in the airway. These in vivo results suggest a mechanism for downstream IL-33 release through which GLP-1R signaling downregulates innate allergic inflammation. However, we could not detect GLP-1R protein expression on ILC2s in the lungs and BMCMCs of naive GLP-1R/mApple reporter mice, raising a concern about the specificity of the anti-GLP-1R antibody that has been used in immunohistochemistry and flow cytometry. Previous studies reported that GLP-1R was expressed in mouse peritoneal macrophages, the human monocyte cell line THP-1, 32 and the human invariant natural killer T cell line. 48 Because GLP-1R protein expression levels on immune cells are not fully known, further experiments are necessary to determine the mechanisms of the anti-inflammatory effect of GLP-1R signaling.
In our 4 consecutive days of the Alternaria extract challenge model, the number of IL-5-and IL-13-expressing CD4 T cells was statistically significantly less than the number of IL-5-and IL-13-expressing ILC2s, and our previous report showed that total IgE and antigen-specific IgG 1 levels in serum were no different between naive mice and mice challenged with Alternaria extract for 4 consecutive days. 40 This supports the concept that the innate immune system and not adaptive immunity initiates and promotes type 2 allergic airway inflammation in this mouse model of allergen challenge. Taken together, our findings reveal that GLP-1R signaling suppresses aeroallergen-driven IL-33 release and inhibits ILC2-dependent innate type 2 airway inflammation. Currently, biological agents are in development to antagonize IL-33 for the treatment of atopic dermatitis, food allergy, and asthma. 9 Our results suggest that a currently FDA-approved GLP-1R antagonist inhibits allergen-induced IL-33 release and expression.
In conclusion, we found that GLP-1R agonist treatment downregulated IL-33 release and expression and innate allergic airway inflammation, including lung eosinophilia, mucus hypersecretion, and AR, after 4 consecutive days of Alternaria extract challenge. Our results suggest that GLP-1R agonists might constitute a novel therapeutic approach for allergic asthma induced by protease-containing aeroallergens.
We thank Dr Andrew N. J. McKenzie, MRC Laboratory of Molecular Biology, Cambridge University, Cambridge, United Kingdom, for providing IL-33
Citrine/Citrine mice.
Key messages
d The GLP-1R agonist inhibits IL-33 release and expression in response to aeroallergen challenge.
d GLP-1R signaling inhibited aeroallergen-induced ILC2 cytokine production, eosinophilic inflammation, mucus metaplasia, and AR.
d A current FDA-approved pharmacologic agent, GLP-1R agonist, might be a novel therapeutic approach for allergic airway disease through blocking IL-33 release into the airway and inhibition of type 2 inflammation.
METHODS
RT-PCR
Human lung tissue was obtained from lungs of deceased organ donors whose lungs were not used for transplantation. Lungs were resected at the time of operative procurement of other organs for transplantation and transported to the laboratory inflated and cooled to 48C. Once received, samples of lung tissue were procured from grossly normal areas of the lung and preserved in RNAlater solution (Thermo Fisher Scientific, Waltham, Mass) for gene expression analysis. For this analysis, lung tissue was used only from donors with normal or near-normal lung histology after review by a clinical pathologist. Mouse lungs were harvested from naive WT BALB/c mice.
Total RNA was isolated by using the RNeasy Mini Kit (Qiagen, Valencia, Calif) from frozen human lung tissues with RNAlater and fresh mouse lungs. cDNA was synthesized by using SuperScript III (Invitrogen, Carlsbad, Calif), according to the manufacturer's instructions. One microliter of RT product was amplified in the presence of GoTaq DNA polymerase (Promega, Madison, Wis) with the QuantiTect Primer Assay. The following primers were purchased from Qiagen: human glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs_GAPDH_1_SG), human GLP1R (Hs_GLP1R_1_SG), mouse Gapdh (Mm_Gapdh_3_SG), and mouse Glp1r (Mm_Glp1r_1_SG). The GAPDH PCR cycling conditions were 958C for 2 minutes, followed by 37 cycles of 948C for 15 seconds, 558C for 30 seconds, and 728C for 30 seconds. The GLP1R PCR cycling conditions were 958C for 2 minutes, followed by 42 cycles of 948C for 15 seconds, 558C for 30 seconds, and 728C for 30 seconds. PCR products were separated by using 2% agarose gel electrophoresis and visualized by using ethidium bromide staining.
Quantitative real-time PCR
Total RNA was isolated from mouse lungs by using the RNeasy Kit (Qiagen), and cDNA was synthesized with SuperScript III (Invitrogen, Carlsbad, Calif). Quantitative real-time PCR analyses were performed with the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) and iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, Calif) with the QuaniTect Primer Assay (mouse Gapdh [Mm_Gapdh_3_SG] and mouse Duox1 [Mm_Duox1_1_SG]), according to the manufacturer's instructions. Quantified concentrations of PCR amplicon were serially diluted and used as standards to determine copy numbers of Duox1. Duox1 data were normalized by using Gapdh expression levels in each sample.
Generation of BMCMCs
BMCMCs were generated, as previously described with modifications.
E1
Briefly, bone marrow cells were obtained by flushing the femurs of GLP-1R/mApple reporter and WT mice. Bone marrow cells were cultured at 378C in a humidified atmosphere containing 5% CO 2 in RPMI 1640 medium with 10 ng/mL IL-3 (PeproTech, Rocky Hill, NJ), 10% FBS, 2 mmol/L L-glutamine, 50 nmol/L b-mercaptoethanol, 100 U/mL penicillin, and 100 mg/mL streptomycin. Every 3 or 4 days, two thirds of the floating cell suspension was transferred to a new flask to remove adherent cells, and fresh culture medium (one third of total media) was added. After 3 weeks, the floating cells were used for flow cytometry to detect GLP-1R/mApple protein expression.
Cell differential counting
Cytospin preparations of BAL fluid cells were performed for each sample. The slides were stained with a Richard-Allan Scientific Three-Step Stain Kit (Thermo Fisher scientific) to determine cell differentials. Differential counts were based on counting 200 cells per slide.
Histologic analyses of lung sections
Forty-eight hours after the last challenge with Alternaria extract or PBS, mice were killed, and lung tissue was fixed in 10% formalin solution, paraffin embedded, cut into 5-mm sections, mounted, and stained with anti-major basic protein antibody that was generously provided by Dr James J. Lee (Mayo Clinic, Scottsdale, Ariz) to evaluate eosiniophils. E2 Slides were examined by a pathologist blinded to experimental groups. Eosinophil scores were as follows: 0, no eosinophils observed in the examined sections; 1, rare perivascular eosinophils; 2, few perivascular eosinophils and scattered eosinophils in the interstitium; 3, moderate number of eosinophils in the perivascular space and in interstitium; and 4, marked eosinophils in the perivascular space, interstitium, and alveolar spaces.
In addition, paraffin-embedded lung tissue slices were stained with periodic acid-Schiff (PAS) solution to visualize mucus and mucus-producing cells. 
AR measurement
Mice were anesthetized with pentobarbital sodium (105 mg/kg), a tracheostomy tube was placed, and the internal jugular vein was cannulated. Mice were ventilated mechanically in a plethysmographic chamber. Lung resistance was measured after intravenous administration of acetyl-bmethacholine chloride (0-411 mg/kg; Sigma-Aldrich, St Louis, Mo), as previously described. Fig E1, A) , LDH activity (Fig E1, B) , CysLT levels (Fig E1, C) , and PGD 2 levels (Fig E1, D) in BAL fluid from WT and IL-33 knockout mice 1 hour after the first Alternaria extract challenge after GLP-1R agonist or vehicle treatment (n 5 3 for PBS-challenged groups and n 5 5 for Alternaria extract-challenged groups). *P < .05 compared with vehicle-Alternaria extract-challenged group. E, Gating strategy of BMCMCs. BMCMCs were identified by using flow cytometry as 
